Aristotle University Of Thessaloniki (AUTH)
Ο ρόλος των αγγειοδραστικών παραγώγων του αραχιδονικού οξέος στη λιπιδική υπεροξείδωση των ουραιμικών ασθενών
Abstract
dc:descriptionIntroduction: Arachindonic acid (a.a.), a multi-unsaturated fatty acid that consists of 20 atoms of carbon and 4 double bonds, is found mainly in the phospholipids of the cellular membranes of the tissues, from where it is freed by the activation of phospholipase A₂. A.a. is metabolized into its potent biological products, in a different way from tissue to tissue, mainly through the action of cyclooxygenases (COX-I and COX-ΙΙ), however, through its non-enzymic lipid peroxidation as well, as was recently found. The most important vasoactive derivatives of a.a. which are induced by the action of COX-I and COX-ΙΙ are the eicosanoids hormones: a) Prostaglandine Ε₂ (PGE₂), a vasodilative local hormone that regulates the hemodynamic parameters of the kidneys, b) Prostacycline Ι₂ (PGI₂), a hormonal vasodilative biomolecule, produced in the endothelium of the vessels and related with their atheromatosis, c) Thromboxane Α₂ (ΤΧΑ₂), a hormonal vasocontractive biomolecule which is produced by the platelets, causes their accumulation and is related with pathological conditions that result to their activation. The most important product of a.a. which derives from its non-enzymic lipid peroxidation is 15-F₂t-Isoprostane (15-F₂t-IsoP), a powerful vasocontractive biomolecule of the kidneys, which belongs to the family of F₂-isoprostanes with 64 diastereoisomere. The vasoactive derivatives of a.a. which are due to the action of cycloxygenases, and those produced by its non-enzymic peroxidation, are probably interrelated and play a role in the lipid peroxidation in the uremic patients. The aim of this study was to investigate the role of the vasoactive eicosanoids hormones, derivatives of a.a., in the lipid peroxidation in chronic uremic patients and examine the possible relation between its enzymic and non-enzymic derivatives in the lipid peroxidation in the above-mentioned patients. Material and methods: We have studied 135 uremic patients with different severity of renal failure, 85 men and 50 women, and 35 normal controls, 25 men and 10 women. The healthy individuals were divided into two groups, the first group (N.C.) and the second group (N.C./I.F.). Group N.C. consisted of 29 healthy subjects, 19 men and 10 women, aged 46,5±9,4 years, and group N.C./I.F. consisted of 6 healthy subjects, men aged 47,7±5,9 years, in which as biologically examined fluid we used – besides the plasma – the intracellular fluid (I.F.) of the muscles as well. The uremic patients were divided into six groups: the first group (CRF₁), the second CRF₂, the third CRF₃, the fourth ΤΝ, the fifth ΤΝ/ΕRG and the sixth ΤΝ/I.F. Group CRF₁ consisted of 22 patients, 13 males and 9 females, aged 57,6±9,4 years, with Chronic Renal Failure (CRF) and creatinine clearance 90-60 ml/min. Patient group CRF₂ consisted of 34 patients, 21 men and 13 women, aged 63,0±11,2 years, with CRF and creatinine clearance 60-30 ml/min. Patient group CRF₃ consisted of 29 patients, 16 men and 13 women, aged 64,0±13,0 years, with CRF and creatinine clearance 30-15 ml/min. Group ΤΝ consisted of 31 patients, 21 men and 10 women, aged 58,9±15,8 years, with creatinine clearance ≤ 5,0 ml/min, who were on chronic periodic hemodialysis 3 times a week for time period of 4 hours each time. Patient group ΤΝ/ΕRG consisted of 13 patients, 8 men and 5 women, aged 60,1±9,8 years, who participated in a physical training programme using a special stationary bicycle during their hemodialysis, for at least six months. Patient group ΤΝ/I.F. consisted of 6 men aged 52,3±6,2 years who were on chronic periodic hemodialysis; besides the plasma, the intracellular fluid (i.f.) of the muscles of the patients examined was used as biologic fluid for the measurement of 15-F₂t-IsoP (8-iso-PGF₂ₐ). In healthy controls, as well as in uremic patients, the plasma levels of 15-F₂t-IsoP, thromboxane Β₂ (ΤΧΒ₂), PGE₂, the stable derivative of PGI₂, 6-keto-PGF₁ₐ, vitamin E and the blood serum levels of the Total Antioxidative Ability (T.A.A.), as well as the 15-F₂t-IsoP levels in the muscle I.F. (in the group N.S./I.F. and ΤΝ/IF), were calculated by using modern biochemical and endocrine methods. Results: According to the measurements of the biochemical-endocrinological parameters that we studied, we found that: Α. In normal controls of Group N.C. the levels in the plasma or the blood serum. 1) of 15-F₂t-IsoP were 47,11±32,25 pg/ml, 2) of ΤΧ Β₂ 88,22±45,27 pg/ml, 3) of PGE₂ 6,59±1,87 pg/ml, 4) of 6-keto-PGF₁ₐ 177,00±106,55 pg/ml, 5) of vitamin Ε 31,09±6,16 μmol/l, 6) of T.Α.A. 1,05±0,08 mmol/l. Β. In the normal controls of group N.C./Μ.Υ. the 15-F₂t-IsoP plasma levels were 25,6±5,1 pg/ml and in the IF 21,1±4,1 pg/ml. C. In patients with creatinine clearance 90-60 ml/min in group CRF1 the levels in the plasma and in the blood serum. 1) of 15-F₂t-IsoP were 259,73±62,11 pg/ml, 2) of ΤΧ Β₂ 279,10±48,29 pg/ml, 3) of PGE₂ 12,89±4,04 pg/ml, 4) of 6-keto-PGF₁ₐ 423,61±114,41 pg/ml, 5) of vitamin Ε 22,86±3,27 μmol/l , 6) of T.Α.A. 1,05±0,08 mmol/l. D) In patients with creatinine clearance 60-30 ml/min in group CRF₂ the plasma and blood serum levels. 1) of 15-F₂t-IsoP were 317,45±107,61 pg/ml, 2) of ΤΧ Β₂ 336,05±96,98 pg/ml , 3) of PGE₂ 14,35±4,50 pg/ml, 4) of 6-keto-PGF₁ₐ 584,69±260,54 pg/ml, 5) of vitamin Ε 22,56±4,89 μmol/l 6) of Ο.Α.Ι. 1,04±0,11 mmol/l. Ε) In patients with creatinine clearance 30-15 ml/min in group CRF₃ the plasma and blood serum levels. 1) of 15-F₂t-IsoP were 412,82±99,76 pg/ml, 2) of ΤΧ Β₂ 363,90±164,41 pg/ml, 3) of PGE₂ 15,48±4,56 pg/ml, 4) of 6-keto-PGF₁ₐ 750,31±339,68 pg/ml, 5) of vitamin Ε 20,84±1,84 μmol/l, 6) of T.Α.A. 1,03±0,14 mmol/l. F) In patients who were on chronic periodic hemodialysis, group ΤΝ, the plasma and blood serum levels. 1) of15-F₂t-IsoP before the hemodialysis were 483,07±162,21 pg/ml of plasma and after hemodialysis 524,34±319,93 pg/ml, 2) of ΤΧ Β₂ before the hemodialysis were 616,70± 160,23 pg/ml and after the hemodialysis 430,76±134,67 pg/ml, 3) of PGE₂ before the hemodialysis were 17,68±5,36 pg/ml and after the hemodialysis 16,57±4,97 pg/ml, 4) of 6-keto-PGF₁ₐ before the hemodialysis were 1295,10±384,43 pg/ml and after hemodialysis 1005,61± 555,49 pg/ml, 5) of vitamin Ε before the hemodialysis were 26,85±1,54 pg/ml and after the hemodialysis 27,56 ± 1,73 pg/ml and 6) of T.Α.A. before the hemodialysis were 0,93 ± 0,15 pg/ml and after the hemodialysis 0,81±0,12 pg/ml. G) In the patients of group ΤΝ/ΕRG who were on a physical training programme during hemodialysis the plasma and blood serum levels. 1) of 15-F₂t-IsoP before the hemodialysis were 414,95±105,69 pg/ml and after the hemodialysis 313,19±56,11 pg/ml, 2) of ΤΧΒ₂ before the hemodialysis were 508,20±167,53 pg/ml and after the hemodialysis 348,91±60,1 pg/ml, 3) of PGE₂ before the hemodialysis were 20,25±5,78 pg/ml and after the hemodialysis 22,44±5,71 pg/ml, 4) of 6-keto-PGF₂ₐ 1445,21±555,49 pg/ml and after the hemodialysis 1613,18±435,69 pg/ml, 5) of vitamin Ε before the hemodialysis were 27,11±2,60 μmol/l and after the hemodialysis 27,80±2,16 μmol/l and 6) of T.Α.A. before the hemodialysis were 0,91±0,11 μmol/l and after the hemodialysis 0,79±0,08 μmol/l. H) In the patients on hemodialysis of group Τ.Ν./I.F. the 15-F₂t-IsoP plasma levels before hemodialysis were 330,4±42,2 pg/ml and after hemodialysis 549,0±64,4 pg/ml. Additionally, the 15-F₂t-IsoP levels of the patients on hemodialysis in the I.F. before hemodialysis were 150,1±22,2 and after hemodialysis 272,0±31,8 pg/ml I.F. Conclusion: Based on this study we draw the following conclusions: 1. Oxidative stress and lipid peroxidation in patients with CRF begin from the first stages of the disease, increase along with the decrease in renal function and remain high in the hemodialysed patients before and after hemodialysis. The level of lipid peroxidation in the I.F. of the patients on hemodialysis was half of that in the plasma and expresses the oxidative stress of these patients accumulatively for a certain period of time. 2. The degree of the oxidative stress and the lipid peroxidation of hemodialysed who take part in a mild physical training programme during the hemodialysis, for long, is noticeably lower than the degree of oxidative stress and lipid peroxidation of hemodialysed patients who do not participate in similar physical training programmes. 3. The activation of the platelets and the production of thromboxane Α₂ (ΤΧΑ₂) in the patients with CRF start from the first stages of the disease, increase along with the deterioration of renal function and remain even more elevated in the patients on hemodialysis, especially before their hemodialysis. 4. The production level of the vasocontractive derivative of the a.a. ΤΧΑ₂ in the hemodialysed patients who participate for a long period of time in a programme of mild physical training during the hemodialysis, is significantly lower than the level of production of thromboxane Α₂ in hemodialysed patients who do not take part in similar physical training programmes. 5. The lipid peroxidation and thromboxane Α₂ increase in CRF patients who are in different stages of renal failure are in parallel and there is an important correlation between them in the above-mentioned patients. The measurement of the levels of isoprostane 15-F₂t-IsoP and thromboxane Β₂ in the plasma of patients with CRF is very useful and constitutes highly important biochemical-endocrinological indices of the gravity of the disease and the morbidity of these patients. 6. The increase in the biosynthesis of prostaglandine Ε₂ (PGE₂) and prostacycline Ι₂ (PGI₂) in CRF patients who are in different stages of renal failure start from the first stages of the disease, increase along with the deterioration of renal function and remain even more elevated in the patients on hemodialysis, especially before their hemodialysis. 7. The percent of increases of the vasoactive arahidonic acid derivatives in the hemodialyzed patient who participated in a physical training programme during hemodialysis (for long time) was higher than the percent of increases in the hemodialyzed patient who were not in the above programme. 8. The decrease in the levels of vitamin E in CRF patients who are in different stages of renal failure begins from the first stages of the disease and improves considerably in the hemodialysed patients. 9. The total antiperoxidative ability in the plasma of CRF patients who are in different stages of renal failure does not change with the deterioration of the renal function; yet it is significantly lower in its end stage that is in the patients on hemodialysis. 10. The increase of lipid peroxidation in patients with renal failure of different gravity is in close relation with the increase in biosynthesis of vasoactive derivatives of arachidonic acid, thromboxane Α₂, prostaglandine Ε₂ and prostacycline Ι₂.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Karamouzis, Ioannis
- Καραμούζης, Ιωάννης
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/20941